Pharmafile Logo
Pharmafocus logo
Advanced Search

Medical Communications

Showing 15 posts of 6402 posts found.

alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
News
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016 Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
News
shutterstock_235920349

NICE and the CDF: Are they still up to scratch?

October 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CDF, Cancer Drugs Fund, NICE

Originally published in the October issue of Pharmafocus, Matt Fellows explores medical and pharmaceutical opinion of the divisive institute to …
Feature
david_goldstein

Professor David Goldstein appointed as chief adviser for AstraZeneca’s genomics initiative

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

AstraZeneca today announced that Professor David Goldstein will join the Company in the consultative role of Chief Adviser, Genomics to …
Appointment
oncology_no_border

Pharmafocus: Advances in Oncology available now!

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, oncology, pharmafocus supplement

The latest issue of Pharmafocus is now available, and with it comes Advances in Oncology, our supplement featuring all the …
News
top_ten_stories

Top Ten articles in the Pharma Industry this week

September 30, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Coming towards the end of September, we’ve had some major developments in drug trials and bad news for some of …
News
cancer_drugs_-_credit_derek_k

€10.2 billion lost every year across the EU due to fake medicines

September 30, 2016 Manufacturing and Production, Medical Communications EU, European Union Intellectual Property Office, France, Germany, Italy, Spain, united kingdom

A report commissioned by the European Union Intellectual Property Office has shown that a staggering amount of money, €10.2 billion, …
News
download

Hanmi Pharma shares crash after shock contract termination

September 30, 2016 Manufacturing and Production, Medical Communications, Research and Development Boehringer Ingelheim, Genentech, Germany, HM61713, Hanmi Pharmaceutical, Tagrisso, south korea

News broke on 29 September that Hanmi Pharma, South Korea’s leading drug maker, had signed a $910 million deal with …
News

NICE rejects Lilly lung cancer drug, recommends Bayer’s Xofigo and Amgen’s Imlygic

September 30, 2016 Medical Communications, Sales and Marketing Imlygic, NICE, Portrazza, xofigo

The National Institute of Health and Care Excellence has issued final guidance rejecting Eli Lilly’s Portrazza (necitumumab) for the treatment …
News
brian_mcnamara

GSK appoints Brian McNamara chief of consumer health division

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Brian McNamara, Emma Walmsley, GlaxoSmithKline

GlaxoSmithKline PLC has named Brian McNamara the head of its consumer-health division. The new comes a week after the announcement …
Appointment
abbvie-singapore

AbbVie opens its $300 million manufacturing plant in Singapore

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, Asia, Singapore

AbbVie’s new Singapore based manufacturing plant is expected to be fully operational by late 2018. The plant is expected to …
News

The October issue of Pharmafocus is now live!

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Pharmafocus, Pharmafocus new issue

The latest edition of Pharmafocus is available online now.
News
janssen_stairs_1

Johnson & Johnson failed to inform FDA over faulty blood testing device in Phase III trial

September 29, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Bayer, Johnson & Johnson, Xarelto, phase III, warfarin

The British Medical Journal, after its own investigation, found that Janssen knew early into the Phase III trial, known as …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025